Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Anne M Fagan

Showing results (111-120 of 279) with videos related to

Pageof 28
Sort By:
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2018
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Chengjie Xiong, Eric M McDade, et al.
Biological Psychiatry|February 20, 2014
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluidOscar Harari, Carlos Cruchaga, John S K Kauwe, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2021
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tauOmar H Butt, Karin L Meeker, Julie K Wisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2008
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta depositionJohn S K Kauwe, Carlos Cruchaga, Kevin Mayo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 5, 2018
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imagingSuzanne E Schindler, Julia D Gray, Brian A Gordon, et al.
Scientific Reports|July 7, 2016
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseJulia Muenchhoff, Anne Poljak, Anbupalam Thalamuthu, et al.
Neurology|March 25, 2016
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children StudyChengjie Xiong, Mateusz S Jasielec, Hua Weng, et al.
Plos One|February 25, 2011
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's diseaseJohn S K Kauwe, Carlos Cruchaga, Celeste M Karch, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Brain : a Journal of Neurology|March 27, 2018
Data-driven models of dominantly-inherited Alzheimer's disease progressionNeil P Oxtoby, Alexandra L Young, David M Cash, et al.
Pageof 28

Showing results (111-120 of 279) with videos related to

Sort By:
Pageof 28
Alzheimer'S & Dementia (New York, N. Y.)|December 21, 2018
Simultaneously evaluating the effect of baseline levels and longitudinal changes in disease biomarkers on cognition in dominantly inherited Alzheimer's diseaseGuoqiao Wang, Chengjie Xiong, Eric M McDade, et al.
Biological Psychiatry|February 20, 2014
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal fluidOscar Harari, Carlos Cruchaga, John S K Kauwe, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|May 18, 2021
Network dysfunction in cognitively normal APOE ε4 carriers is related to subclinical tauOmar H Butt, Karin L Meeker, Julie K Wisch, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 11, 2008
Variation in MAPT is associated with cerebrospinal fluid tau levels in the presence of amyloid-beta depositionJohn S K Kauwe, Carlos Cruchaga, Kevin Mayo, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 5, 2018
Cerebrospinal fluid biomarkers measured by Elecsys assays compared to amyloid imagingSuzanne E Schindler, Julia D Gray, Brian A Gordon, et al.
Scientific Reports|July 7, 2016
Changes in the plasma proteome at asymptomatic and symptomatic stages of autosomal dominant Alzheimer's diseaseJulia Muenchhoff, Anne Poljak, Anbupalam Thalamuthu, et al.
Neurology|March 25, 2016
Longitudinal relationships among biomarkers for Alzheimer disease in the Adult Children StudyChengjie Xiong, Mateusz S Jasielec, Hua Weng, et al.
Plos One|February 25, 2011
Fine mapping of genetic variants in BIN1, CLU, CR1 and PICALM for association with cerebrospinal fluid biomarkers for Alzheimer's diseaseJohn S K Kauwe, Carlos Cruchaga, Celeste M Karch, et al.
JAMA Neurology|September 15, 2015
Neurogranin as a Cerebrospinal Fluid Biomarker for Synaptic Loss in Symptomatic Alzheimer DiseaseMaartje I Kester, Charlotte E Teunissen, Daniel L Crimmins, et al.
Brain : a Journal of Neurology|March 27, 2018
Data-driven models of dominantly-inherited Alzheimer's disease progressionNeil P Oxtoby, Alexandra L Young, David M Cash, et al.
Pageof 28